Spero Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SPRO research report →
Companysperotherapeutics.com
Spero Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.
- CEO
- Esther Rajavelu
- IPO
- 2017
- Employees
- 32
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $152.28M
- P/E
- 9.89
- P/S
- 2.78
- P/B
- 2.85
- EV/EBITDA
- 6.98
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- 24.66%
- Net Margin
- 27.82%
- ROE
- 35.58%
- ROIC
- 23.93%
Growth & Income
- Revenue
- $59.62M · 24.27%
- Net Income
- $8.57M · 112.50%
- EPS
- $0.15 · 111.81%
- Op Income
- $-24,000
- FCF YoY
- 46.15%
Performance & Tape
- 52W High
- $3.22
- 52W Low
- $0.66
- 50D MA
- $2.57
- 200D MA
- $2.32
- Beta
- 1.43
- Avg Volume
- 443.21K
Get TickerSpark's AI analysis on SPRO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 4, 26 | Rajavelu Esther | sell | 25,240 |
| Feb 6, 26 | Rajavelu Esther | sell | 37,101 |
| Feb 6, 26 | Rajavelu Esther | sell | 50,816 |
| Feb 6, 26 | Keutzer Timothy | sell | 18,652 |
| Feb 2, 26 | Keutzer Timothy | other | 68,000 |
| Feb 2, 26 | Keutzer Timothy | sell | 18,891 |
| Feb 3, 26 | Keutzer Timothy | sell | 24,224 |
| Feb 4, 26 | Keutzer Timothy | sell | 3,471 |
| Feb 2, 26 | Keutzer Timothy | other | 137,000 |
| Feb 2, 26 | Rajavelu Esther | other | 249,000 |
Our SPRO Coverage
We haven't published any research on SPRO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SPRO Report →